What Fluvoxamine Actavis Treats: Main Uses and Benefits

Fluvoxamine Actavis is a treatment primarily designed to provide symptomatic relief and stabilization for conditions involving chronic, disruptive thought and anxiety patterns. Its use focuses on easing the intense burden of specific psychological symptoms and assists with maintaining functional stability. The therapeutic application of the medication includes managing symptoms of obsessive-compulsive disorder (OCD) and social anxiety disorder.

---

Reducing the Burden of Obsessions and Compulsions

This medication is commonly applied to conditions presenting with acute episodes and marked by heightened patient distress, specifically Obsessive-Compulsive Disorder (OCD). It helps address symptom clusters that may become intense or disruptive, such as distressing, unwanted obsessive thoughts and the urge to perform compulsive rituals. Fluvoxamine provides support that contributes to easing the overall symptom load during these manifestations. This treatment is relevant for conditions characterized by periods of heightened symptoms, including OCD and Social Anxiety Disorder.

“Its application is considered relevant for easing the functional strain caused by chronic and disruptive symptom patterns.”

---

Stabilizing Severe Social and Avoidance Anxiety

Fluvoxamine is relevant in clinical settings that involve acute or unstable symptom patterns, such as the intense manifestations of Social Anxiety Disorder (social phobia). It may assist with managing symptoms like overwhelming fear of scrutiny and excessive avoidance behaviors. This provides supportive relief when symptoms interfere with routine activities and may assist with maintaining a sense of stability when symptoms are more noticeable. Its use is considered relevant for managing symptoms in adults, and is commonly used in children and adolescents (aged 8 and older) for OCD.

Therapeutic Focus: Obsessive-Compulsive Symptoms
Therapeutic Context: Commonly used in situations involving distressing symptoms of OCD and severe social anxiety.
Symptom Focus: Helps address symptoms that create noticeable functional strain, such as intrusive thoughts and avoidance behaviors.
Primary Benefit: Provides supportive relief when symptoms interfere with routine activities and may assist with maintaining functional stability.

Regulatory References

1. NIH MedlinePlus overview of Fluvoxamine

Who Can and Cannot Use Fluvoxamine Actavis?

The population eligibility for Fluvoxamine Actavis is defined strictly by official regulatory labeling, outlining specific contraindications, age restrictions, and conditions requiring caution.

Fluvoxamine Actavis is contraindicated in patients with a known hypersensitivity to the drug or who are concurrently using a Monoamine Oxidase Inhibitor (MAOI). Use is also strictly prohibited with certain drugs, including Tizanidine, Pimozide, Thioridazine, and Alosetron.

Eligibility by Age and Condition

Population Group	Eligibility Status
Adults (OCD & Social Anxiety)	Approved for use.
Children ge 8 years (OCD)	Approved for Obsessive-Compulsive Disorder only.
Children <8 years	Safety and efficacy not established for OCD.
Elderly Patients	Requires caution and close monitoring (increased risk of hyponatremia).

Patients with unstable epilepsy should avoid the medicine, while those with controlled epilepsy require careful monitoring. Similarly, patients with hepatic or renal insufficiency must be closely monitored and started on the lowest dose, as specified in regulatory documents.

Pregnancy and Lactation

Fluvoxamine is formally documented as being secreted in human breast milk. Use during the third trimester of pregnancy carries an officially stated risk of persistent pulmonary hypertension and symptoms of poor neonatal adaptation in the newborn.

Fluvoxamine Actavis Interactions with other medicines and products

Fluvoxamine can alter the activity of certain liver enzymes, leading to clinically significant interactions with numerous medicinal products. The drug is a potent inhibitor of CYP1A2 and, to a lesser extent, a moderate inhibitor of CYP2C19 and CYP3A4, which increases the plasma concentrations of substrates for these enzymes.

Contraindicated Combinations and Serotonergic Agents:

Fluvoxamine must not be used concurrently with Monoamine Oxidase Inhibitors (MAOIs), including selegiline. A washout period of at least two weeks is mandatory when switching from an MAOI, and at least one week when switching to an MAOI. Co-administration with the drugs pimozide, tizanidine, ramelteon, thioridazine, or alosetron is also contraindicated. Use with other serotonergic agents (e.g., triptans, tramadol, lithium, tryptophan, St. John’s Wort) requires caution due to the potential for Serotonin Syndrome.

Interactions Requiring Dose Adjustment or Monitoring:

Increased drug exposure is seen with substrates of the inhibited enzymes, including clozapine, theophylline, caffeine, methadone, ropinirole, certain Tricyclic Antidepressants (e.g., imipramine, clomipramine), phenytoin, and some benzodiazepines (e.g., alprazolam, triazolam). A dose reduction is often required for the co-administered drug. The combination with oral anticoagulants (e.g., warfarin), NSAIDs, or other antiplatelet agents increases the risk of bleeding and requires close monitoring of coagulation parameters.

Fluvoxamine Actavis is a medication that modulates key signaling pathways in the central nervous system to alter the functional status of chemical messengers. Its action involves two primary, complementary mechanistic domains.

Modulating Serotonin Availability through SERT Inhibition

This domain centers on the Serotonin Transporter (SERT), which mediates the reuptake of serotonin from the synaptic space. Fluvoxamine Actavis engages mechanisms that selectively block SERT, increasing the functional availability of serotonin to engage its postsynaptic receptors, and initiating subsequent signaling cascades that result in altered systemic pathway activity.

---

Regulating Intracellular Stress via Sigma-1 Receptors

The drug uniquely acts within domains involving the Sigma-1 (sigma1) receptor, where it functions as a ligand. This engagement modifies early molecular steps, such as those governing intracellular calcium signaling and mitochondrial function, which alters the influence of cellular stress signals and results in modified regulatory feedback loops within targeted neural pathways.

How to Use Fluvoxamine Actavis

Fluvoxamine maleate is formulated for the oral route of administration, available as immediate-release tablets (25 mg, 50 mg, and 100 mg) and extended-release capsules (100 mg and 150 mg). Administration can occur with or without food, and the dose is typically taken once daily at bedtime.

The therapeutic approach involves a low starting dose followed by gradual titration.

Dosage Form	Starting Dose (Adults)	Titration and Maximum Dose	Dosing Frequency
Immediate-Release Tablet	50 mg at bedtime	Increase by 50 mg every 4 to 7 days, up to 300 mg/day	Doses over 100 mg are divided into two daily administrations; larger dose at bedtime.
Extended-Release Capsule	100 mg at bedtime	Increase by 50 mg at weekly intervals, up to 300 mg/day	Once daily (capsules should not be crushed or chewed).

Special Population and Handling Rules

For pediatric patients aged 8 to 17, the initial dose is 25 mg at bedtime, with gradual increases up to a maximum of 200 mg (ages 8-11) or 300 mg (ages 12-17); doses over 50 mg must be divided. Due to decreased clearance, older adults and individuals with hepatic impairment should begin with a low dose and undergo slower titration.

The discontinuation of the medication typically involves a gradual reduction (tapering) of the dose over a period of weeks rather than stopping abruptly. If a dose is missed, patients should skip the missed dose and resume the regular dosing schedule at the next scheduled time; double doses should not be taken.

Recent Clinical Evidence

Research on Core Symptoms

Research has explored whether fluvoxamine might be associated with improvements in symptoms of its indicated conditions. Studies have primarily examined the compound’s profile in randomized controlled trials (RCTs) over periods typically ranging from 8 to 12 weeks. These trials evaluated changes using established rating scales, such as the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) in its primary use.

Key findings reported in multiple Phase 3 studies indicated that some participants experienced a reduction in symptom severity when compared with a placebo group. The primary endpoint generally measured was the score change on these standardized scales from the study's baseline.

---

Pharmacokinetics and Absorption

Clinical research has characterized the absorption and metabolic profile of fluvoxamine. Studies have evaluated its plasma concentration curves and half-life following oral administration. Data indicated that the compound achieves its peak plasma concentration within a few hours of dosing. Researchers have also examined the effect of the drug on liver enzymes, noting that it can inhibit certain cytochrome P450 enzymes.

---

Safety and Patient-Specific Groups

Researchers conducted specific sub-analyses to examine the drug's safety profile across different patient populations.

• Geriatric Population: A post-hoc analysis of pooled RCT data reported that the drug demonstrated a safety profile in older adults (age 65 and above) consistent with that observed in the general study population.
• Adverse Events: Commonly reported adverse events included nausea, drowsiness, and headache. Reports of more severe events, though less frequent, were noted.
• Hepatic Impairment: Research examined its profile in people with hepatic impairment. Findings reported that the plasma clearance of fluvoxamine may be reduced in participants with liver dysfunction, suggesting careful consideration in this population.

Key Studies & References

1. NICE Guideline NG137: Obsessive-compulsive disorder and body dysmorphic disorder: treatment

Common questions about Fluvoxamine Actavis (FAQ)

Q: How quickly do people usually start feeling an effect from Fluvoxamine?

A: Studies indicate that the first signs of improvement in symptoms may begin within 4 to 6 weeks of starting treatment. However, it is also noted that some individuals may require a period of 10 to 12 weeks or longer to notice a significant therapeutic effect.

Q: Is Fluvoxamine Actavis the same as Luvox?

A: Fluvoxamine Actavis is a generic formulation of the active ingredient, fluvoxamine maleate. This is the same active chemical compound found in the former brand-name medicine, Luvox (or Luvox CR), according to regulatory documentation.

Q: Are there any specific foods or drinks to avoid while taking Fluvoxamine Actavis?

A: Official labeling advises avoiding alcohol consumption during treatment due to the potential for increased sedation. Additionally, Fluvoxamine interacts with caffeine by affecting how the body processes it, and intake of caffeine may need to be adjusted.

Q: What kind of research has been done on Fluvoxamine Actavis for social anxiety?

A: Fluvoxamine is approved for use in adults with Social Anxiety Disorder. Efficacy studies supporting this use typically evaluate the effect using standardized rating scales over short-term (e.g., 8–12 week) treatment periods.

Q: How long does Fluvoxamine Actavis stay in your system after stopping it?

A: The elimination of the drug is characterized by its average plasma half-life. Regulatory documents indicate this is approximately 15 hours after a single dose, which may be extended to 17–22 hours with repeated dosing at steady-state.

Q: Does Fluvoxamine Actavis have a 'black box' warning, and what is it for?

A: Yes, the FDA label includes a Boxed Warning (sometimes called a 'Black Box' Warning) regarding the risk of suicidal thinking and behavior in children, adolescents, and young adults (up to age 24) when starting antidepressant treatment or having their dose changed.

Q: What is the difference between Fluvoxamine Actavis and other antidepressants like tricyclics?

A: Fluvoxamine belongs to the SSRI class, which primarily inhibits serotonin reuptake. Compared to older classes like tricyclic antidepressants, official documents suggest SSRIs generally have a lower incidence of certain side effects, such as anticholinergic effects.

Q: What is the role of fluvoxamine in treating conditions other than anxiety disorders?

A: Fluvoxamine is officially approved by the FDA only for the treatment of Obsessive-Compulsive Disorder (OCD) in children and adults, and Social Anxiety Disorder in adults. Its role in other conditions is not listed on its regulatory label.

Q: Can this medication affect alertness during the day?

A: Yes, the medication may cause side effects like drowsiness, dizziness, or sleepiness, and regulatory information indicates it can impair alertness, judgment, and motor skills. Official regulatory information advises caution regarding activities like driving or operating hazardous machinery.

Q: What is serotonin syndrome, and is it a risk with Fluvoxamine Actavis?

A: There is a documented risk for Serotonin Syndrome, especially when combined with other medicines that also affect serotonin levels. This potentially serious condition is characterized by symptoms such as agitation, high blood pressure, sudden changes in body temperature, and severe muscle convulsions.

Q: What is the expected timeline for maximum effect of the medicine?

A: While some therapeutic effects may be observed within the first few weeks, the full benefit is typically assessed in clinical trials after 8 to 12 weeks of continuous use. This period is often required to achieve and evaluate the maximum therapeutic effect.

Q: Is Fluvoxamine Actavis a controlled substance in the US or UK?

A: No, Fluvoxamine Actavis is generally classified as a prescription-only medicine. It is not designated as a controlled substance in the US.

Q: Does Fluvoxamine Actavis cause weight gain or weight loss?

A: Official adverse event summaries indicate that unusual weight gain or loss has been reported as a less common side effect.

Q: Is it normal to feel more anxious or restless when first starting Fluvoxamine?

A: Regulatory documents list agitation and restlessness as possible side effects. These reactions may be more noticeable when beginning treatment or when the dose is being adjusted.

Q: Is Fluvoxamine Actavis known to cause sexual side effects?

A: Yes, sexual dysfunction is commonly reported in official adverse event summaries. This may include decreased sexual desire or performance and difficulty achieving or maintaining an erection or orgasm.

Q: Are there warnings about Fluvoxamine Actavis and driving or operating machinery?

A: Yes, official warnings indicate that caution is necessary for activities like driving or operating hazardous machinery due to the risk of impaired cognitive or motor performance.

Q: Is there a risk of developing dependence on Fluvoxamine Actavis?

A: Fluvoxamine is not classified as a controlled substance and is generally considered to have a low risk for abuse or dependence. However, regulatory guidelines mandate that the dose be gradually reduced (tapered) when stopping the medicine to minimize symptoms.

Q: Does taking Fluvoxamine Actavis require regular blood tests?

A: Regular laboratory tests are not universally required for all patients. However, official information indicates that monitoring may be necessary in specific patient populations, such as the elderly (to check sodium levels) or those with hepatic impairment, based on official guidance for their specific health condition.

Q: Is Fluvoxamine Actavis known to interact with blood pressure medications?

A: Yes, Fluvoxamine is known to interact with certain beta-blockers (a class of blood pressure medicine) like propranolol and metoprolol, potentially increasing their concentration and requiring dose adjustment.

Q: Is Fluvoxamine Actavis safe to take if I have glaucoma?

A: Official information indicates that a history of glaucoma or other eye conditions necessitates careful monitoring or caution during treatment. This is because the condition is a factor addressed in prescribing guidelines.

Q: Are there official warnings about combining Fluvoxamine Actavis and alcohol?

A: Yes, official patient counseling information advises patients to avoid alcohol consumption during treatment due to the potential for increased sedation and impaired motor/cognitive function.

Q: Does Fluvoxamine Actavis affect appetite?

A: Regulatory documents list decreased appetite (anorexia) as a possible side effect that some patients may experience while taking this medication.

Q: Is it required to take Fluvoxamine Actavis at the same time every day?

A: The medicine is typically taken once daily, often at bedtime. For therapeutic consistency and to help maintain steady drug levels, consistency in daily administration time is generally recommended.

Q: What are the research findings on long-term use of Fluvoxamine Actavis?

A: Regulatory documents note that the effectiveness and safety of fluvoxamine for long-term use—meaning for periods longer than approximately 10 weeks—have not been systematically evaluated in controlled clinical trials.

Q: Does Fluvoxamine Actavis contain lactose or other common allergens?

A: The specific inactive ingredients (excipients), such as lactose, are listed in the official Patient Information Leaflet or Consumer Medicine Information (CMI). This information is provided in the official documents for review by those with known sensitivities to components like lactose.

Q: Do official prescribing documents mention mood swings as a side effect?

A: Yes, official labeling includes a warning that treatment may cause the activation of mania or hypomania in some individuals. These are states characterized by significant changes or swings in mood.

Q: What are the signs of a serious allergic reaction described for Fluvoxamine Actavis?

A: Signs of a serious allergic reaction (hypersensitivity) described in official labeling include swelling of the face, lips, tongue, or throat (angioedema), which can cause difficulty breathing or swallowing, and severe skin rash (hives).

Fluvoxamine Actavis must be stored at a controlled room temperature, typically between 20^circC and 25^circC (68^circF and 77^circF), to maintain product stability. The medication must be kept in its original container with the lid closed tightly, and must be protected from both high humidity and excessive heat.

Like all medicines, Fluvoxamine must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Fluvoxamine should be disposed of in accordance with local, regional, and national regulations. The medication should preferably be taken to an official drug take-back program. It is important not to flush the tablets or capsules down a toilet or pour them down a drain.